NRGN Neurogen Corporation featured news, full reports, and detailed charts
Neurogen Corporation (NRGN) Wrap Up:
Neurogen Corporation (NASDAQ: NRGN) ("Neurogen" or the "Company"), incorporated under the laws of the State of Delaware in 1987, is a drug discovery and development company focusing on new small molecule drugs to improve the lives of patients suffering from disorders with significant unmet medical need including insomnia, pain, Parkinson’s disease, restless legs syndrome (“RLS”), anxiety, and schizophrenia. Small molecule drugs typically are suitable for oral administration as a pill, while large molecule drugs typically are administered by injection. Neurogen has generated a portfolio of new drug programs primarily through its fully integrated drug discovery and development processes. The Company may, at times, in-license compounds from other pharmaceutical firms with appropriate risk/reward profiles. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f17%2f0000849043-08-000030.html#FIS_BUSINESS"www.neurogen.com
30 Employees
Founded in 1987
Neurogen Corp. (NRGN*(D):NASDAQ)
LAST $0.17 USD
CHANGE TODAY -0.014 -7.61%
VOLUME 207.3K
*(D) = Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
As of 3:59 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Neurogen Corp. (NRGN)
|
OPEN
$0.19
|
PREVIOUS CLOSE
$0.18
|
|
|
DAY HIGH
$0.19
|
DAY LOW
$0.16
|
|
|
52 WEEK HIGH
11/25/08 - $2.07
|
52 WEEK LOW
12/11/08 - $0.06
|
|
|
MARKET CAP
11.7M
|
AVERAGE VOLUME 3 mo
322.3K
|
|
|
DILUTED EPS TTM
$-0.37
|
SHARES OUTSTANDING
69.0M
|
|
|
NRGN Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
NRGN Top Compensated Officers
Mr. Stephen R. Davis
Chief Executive Officer, President, Chief Ope...
Age: 48
Total Annual Compensation: $421.6K
Dr. Thomas A. Pitler Ph.D.
Chief Business and Financial Officer, Princip...
Age: 50
Total Annual Compensation: $273.6K
Dr. Kenneth J. Sprenger M.D., M.B.B.Ch., B.Sc
Senior Vice President of Clinical Development...
Age: 56
Total Annual Compensation: $273.6K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Neurogen Corp. (NRGN)
Neurogen Corp. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009 ; Announces Asset Impairment Charges
11/6/2009
Neurogen Corp. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company has posted a net loss attributable to common stockholders of $1.9 million, or $0.03 per share as compared to a GAAP net loss attributable to common stockholders for the third quarter of 2008 of $31.7 million, or $0.52 per share. On a non-GAAP basis, excluding non-recurring credits relating to restructuring of workforce and the adjustments to fair value of certain assets, net loss for the totaled $2.4 million, or $0.03 per share as compared to a non-GAAP net loss during the third quarter of 2008 of $8.1 million, or $0.13 per share. Operating loss was $2.11 million compared to $11.41 million for the same period a year ago. For the nine months, the company has posted net loss attributable to common stockholders of $20.2 million or $0.30 basic and diluted per share compared to net loss attributable to common stockholders of $60.09 million or $1.24 basic and diluted per share for the same period a year ago. Non-GAAP adjusted net loss was $11.50 million or $0.17 basic and diluted per share compared to Non-GAAP adjusted net loss of $30.69 million or $0.63 basic and diluted per share for the same period a year ago. Total operating revenue was $2.65 million. Operating loss was $20.61 million compared to $46.7 million for the same period a year ago. The company has announced asset impairment charges of $0.41 million compared to $3.17 million for the same period a year ago.
Neurogen Corp., Q3 2009 Earnings Call, Nov--06-2009
11/4/2009
Neurogen Corp., Q3 2009 Earnings Call, Nov-06-2009
Neurogen Corp. Reports Condensed Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2009
08/14/2009
Neurogen Corp. reported condensed consolidated earnings results for the second quarter and six months ended June 30, 2009. On a GAAP basis, including non-recurring matters, Neurogen recognized a net loss attributable to common stockholders for the second quarter of 2009 of $7.5 million, or $0.11 per share as compared to a GAAP net loss attributable to common stockholders for the second quarter of 2008 of $11.8 million, or $0.28 per share. On a non-GAAP basis, excluding non-recurring charges relating to restructuring of workforce and the write down of certain assets, net loss for the second quarter of 2009 totaled $3.9 million, or $0.06 per share on 68.7 million weighted shares outstanding as compared to a non-GAAP net loss during the second quarter of 2008 of $8.5 million, or $0.20 per share on 42.1 million weighted average shares outstanding. Research and development expenses for the second quarter of 2009 decreased to $2.8 million from $8.0 million in the comparable period of 2008. The operating loss was $7.61 million compared to $18.59 million in the previous year period. For the six months ended June 30, 2009, the company reported that net loss attributable to common stockholders was $18.35 million or $0.27 per basic and diluted share compared to net loss attributable to common stockholders was $28.36 million or $0.67 per basic and diluted share in the previous year period. Non-GAAP adjusted net loss was $9.14 million or $0.13 per basic and diluted share compared to adjusted net loss was $22.58 million or $0.54 per basic and diluted share in the previous year period. The operating loss was $18.57 million compared to $35.30 million in the previous year period.
NRGN Competitors
| Company | Last | Change |
| Arena Pharmaceuticals Inc | $3.51 USD | -0.03 |
| Array BioPharma Inc | $2.03 USD | +0.04 |
| Rigel Pharmaceuticals Inc | $7.78 USD | 0.00 |
| Telik Inc | $0.78 USD | -0.01 |
| Vertex Pharmaceuticals Inc | $38.54 USD | -0.38 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | NRGN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 4.4x |
|
| Price/Book | 0.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
NRGN |
||
|
NRGN transactions
| Type Date |
Target |
|
Merger/Acquisition
August 23, 2009 |
-- |
More Recent News About Neurogen Corporation
More news for NRGN
Ligand to Acquire Neurogen for Stock and Contingent Value Rights
SAN DIEGO & BRANFORD, Conn.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - News) and Neurogen Corporation (NASDAQ:NRGN - News) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRsâ€) under four CVR agreements. The CVRs would entitle Neurogen shareholders to cash payments for the sale or licensing of certain assets and the achievement of a specified clinical milestone. The Ligand and Neurogen Boards of Directors have unanimously voted in favor of this transaction. “We are very pleased to be combining Neurogen with Ligand and believe this transaction benefits the stockholders of both companies,†said John L. Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals. “Ligand stockholders will gain access to an attractive partnership with Merck, additional pipeline assets and drug discovery resources, approximately $7 million in net cash ...Click here to read the whole Article (external link)
Ligand Pharmaceuticals agrees to buy Neurogen
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
Neurogen Corporation Announces Webcast of Third Quarter 2009 Financial Results on November 6
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
NEUROGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Sta
Item 1.01. Entry Into a Material Definitive Agreement. Agreement and Plan of Merger On August 23, 2009, Neurogen Corporation, a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as it may be amended and supplemented from time to time, the "Merger Agreement") with Ligand Pharmaceuticals Incorporated, a Delaware corporation ("Parent"), and Neon Signal, LLC, a Delaware limited liability company and wholly-owned subsidiary of Parent ("Merger Sub"). Under the terms of the Merger Agreement, which was approved by the respective boards of directors of each of the Company (the "Company Board") and Parent, Merger Sub will be merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent, and each outstanding share of the Company's common stock will be cancelled and converted into the right to receive a pro-rata portion of (i) Parent common stock valued at $11,000,000, subject to (A) adjustment based on the final cash position of the Company measured against a target cash amount of $7,900,000 as of September 30, 2009, with a $5,000 daily reduction after September 30, 2009 (as adjusted, the "Adjusted Reference Amount"), and (B) a maximum of 4,200,000 shares of Parent common stock to be issued in the Merger, (ii) the net proceeds from the sale of the Company's two active programs for the development of a treatment for Restless Leg Syndrome and Parkinson's disease (the "Aplindore Program"), if the Aplindore Program is sold prior to closing, (iii) the net proceeds from the sale of the real properties currently owned by the Company (the "Real Estate"), if the Real Estate is sold prior to closing, (iv) through contingent value rights ("CVRs"), the net proceeds from the sales of the Real Estate and the Aplindore Program, respectively, if such sales are not completed prior to...Click here to read the whole Article (external link)
Neurogen Corporation Announces Third Quarter 2009 Financial Results and Updates Operations
BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (NASDAQ: NRGN - News), a drug development company historically focused on drugs for psychiatric and neurological disorders, today announced financial and operating results for the quarter ended September 30, 2009. The Company also announced its analysis of results from a previously suspended Phase 2 study of aplindore in Restless Legs Syndrome (RLS) and that it has entered into an agreement to sell all real estate owned by the Company. Stephen R. Davis, President and CEO said, "While we saw indications of efficacy in the RLS study of aplindore, our analysis of both efficacy and tolerability - when considered in the context of observations from similar clinical studies with drugs currently on the market - suggest the partial agonist profile of aplindore would not be differentiated from the full agonists which either are or will be generic by the time aplindore could be launched.â€Mr. Davis continued, “We are pleased to have recently entered into an agreement to sell our real estate at a price higher than we previously estimated and to have concluded the third quarter with financial results in line with our expectations.â€As previously announced, the Company has signed a merger agreement with Ligand Pharmaceuticals, Inc. (“Ligandâ€) pursuant to which the Company will become a wholly-owned subsidiary of Ligand. The Company e...Click here to read the whole Article (external link)
New Star Analyst Rankings for Neurogen Corporation
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...Click here to read the whole Article (external link)
NEUROGEN CORP Files SEC form 10-Q/A, Quarterly Report
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion is intended to further the reader's understanding of the consolidated financial condition and results of operations of Neurogen Corporation ("Neurogen," "the Company," "we," "us," "our"). It should be read in conjunction with the financial statements in this quarterly report on Form 10-Q and our annual report on Form 10-K for the year ended December 31, 2008. Note Regarding Forward-looking Statements Statements that are not historical facts, including statements about the our confidence and strategies, the status of various product development programs, the opportunities to sell assets or the Company, including the Merger, the sufficiency of cash to fund future operations and our expectations concerning our development compounds, drug development technologies and opportunities in the pharmaceutical marketplace are "forward-looking statements" within the meaning of the Private Securities Litigations Reform Act of 1995 that involve risks and uncertainties and are not guarantees of future performance. These risks include, but are not limited to, the risk that the Merger may not close, including the risk that the required Neurogen stockholder approval for the Merger and related transactions may not be obtained, the possibility that expected synergies and cost savings will not be obtained or that litigation may delay the Merger, difficulties or delays in development, testing, regulatory approval, production and marketing of any of our drug candidates, collaborations and alliances, acquisitions or business combinations, the failure to attract or retain key personnel, any unexpected adverse side effects or inadequate therapeutic efficacy of our drug candidates which could slow or prevent product development efforts, competition within our anticipated product markets, our dependence on corporate partners wi...Click here to read the whole Article (external link)
Neurogen Corporation Earnings Call scheduled for 8:30 am ET today
Call DetailsNeurogen Corporation Earnings Conference Call (Q3 2009)Fri, Nov 6, 2009, 8:30 am EasternAbout Neurogen Corporation (NasdaqGM:NRGN)Neurogen Corporation engages in the development of new small molecule drugs for psychiatric and neurological disorders. The company’s clinical development programs include aplindore, which is in Phase II clinical trials for the treatment of Parkinson’s disease and restless legs syndrome; and MK 2295, a VR1 receptor antagonist that is in preclinical development for the treatment of pain and cough. It has a collaboration and licensing agreement with Merck Sharp & Dohme Limited to research, develop, and commercialize small molecule medicines that work by targeting the VR1 receptor; and a licensing agreement with Wyeth Pharmaceuticals to acquire worldwide rights to aplindore. The company was founded in 1987 and is based in Branford, Connecticut.More Info:Quote |Chart |News |Profile |Reports |Research |SEC |Msgs |Insider |Financials | Analyst Ratings...Click here to read the whole Article (external link)
NEUROGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financial Con
Item 1.01. Entry Into a Material Definitive Agreement. On September 18, 2009, Neurogen Corporation ("Neurogen" or the "Company"), Ligand Pharmaceuticals Incorporated ("Ligand") and Neon Signal, LLC ("Merger Sub") entered into an amendment ("Amendment No. 1") to amend a previously announced Agreement and Plan of Merger, dated as of August 23, 2009 (the "Merger Agreement"), among the same parties, pursuant to which Merger Sub will merge with and into Neurogen, with Neurogen surviving the merger and becoming a wholly-owned subsidiary of Ligand (the "Merger"). In Amendment No. 1, the parties clarified the definition of "Target Net Cash Amount" in the Merger Agreement. On November 2, 2009, Neurogen, Ligand and Merger Sub entered into a second amendment ("Amendment No. 2") to the Merger Agreement, pursuant to which the parties extended the outside date by which the Merger must be consummated or abandoned from December 15, 2009 to December 24, 2009. The foregoing summary of Amendment No. 1 and Amendment No. 2 does not purport to be complete and is subject to, and qualified in its entirety by, the full text of Amendment No. 1 and Amendment No. 2 furnished herewith as Exhibit 2.1 and Exhibit 2.2, respectively, each of which is incorporated herein by reference. Additional Information and Where to Find It Ligand has filed with the SEC a Registration Statement on Form S-4, which includes a proxy statement of Neurogen and other relevant materials in connection with the proposed Merger. The proxy statement, which also constitutes a Ligand prospectus, will be mailed to Neurogen stockholders. Neurogen stockholders are urged to read the proxy statement and the other relevant materials because they will contain important information about Ligand, Neurogen and the proposed Merger. The proxy statement and other relevant materials, and any other documents filed by Ligand or Neurogen with the ...Click here to read the whole Article (external link)
NEUROGEN CORP Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
Would you like to leave a comment about Neurogen Corporation NRGN
Find out what social network information about Neurogen Corporation are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Neurogen Corporation there is more great information available at Realpennies.com